ATE491695T1 - Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen - Google Patents
Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungenInfo
- Publication number
- ATE491695T1 ATE491695T1 AT06733153T AT06733153T ATE491695T1 AT E491695 T1 ATE491695 T1 AT E491695T1 AT 06733153 T AT06733153 T AT 06733153T AT 06733153 T AT06733153 T AT 06733153T AT E491695 T1 ATE491695 T1 AT E491695T1
- Authority
- AT
- Austria
- Prior art keywords
- triazine
- oxides
- tricylic
- compositions
- cancer treatment
- Prior art date
Links
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- XEWBWEWIVXWUJP-UHFFFAOYSA-N 1-oxido-1,2,4-triazin-1-ium Chemical class [O-][N+]1=CC=NC=N1 XEWBWEWIVXWUJP-UHFFFAOYSA-N 0.000 abstract 1
- URCJZSOLEVVNTP-UHFFFAOYSA-N 4-oxido-1,2,4-triazin-1-ium 1-oxide Chemical class [O-][N+]1=CC=[N+]([O-])N=C1 URCJZSOLEVVNTP-UHFFFAOYSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
- C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ53915205 | 2005-03-31 | ||
| NZ54255605 | 2005-09-22 | ||
| PCT/NZ2006/000064 WO2006104406A1 (en) | 2005-03-31 | 2006-03-31 | Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE491695T1 true ATE491695T1 (de) | 2011-01-15 |
Family
ID=37053615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06733153T ATE491695T1 (de) | 2005-03-31 | 2006-03-31 | Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7989451B2 (de) |
| EP (1) | EP1866292B1 (de) |
| AT (1) | ATE491695T1 (de) |
| AU (1) | AU2006229566B2 (de) |
| CA (1) | CA2603088C (de) |
| DE (1) | DE602006018883D1 (de) |
| DK (1) | DK1866292T3 (de) |
| WO (1) | WO2006104406A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| WO2013086467A1 (en) * | 2011-12-07 | 2013-06-13 | Sri International | Benzotriazine oxides as drugs targeting mycobacterium tuberculosis |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| EP2999469A1 (de) | 2013-05-23 | 2016-03-30 | Bayer Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen ( on-demand") kontrazeption |
| WO2015091645A1 (en) | 2013-12-18 | 2015-06-25 | Basf Se | Azole compounds carrying an imine-derived substituent |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| CA2456569A1 (en) * | 2003-03-14 | 2004-09-14 | Auckland Uniservices Limited | Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments |
-
2006
- 2006-03-31 AT AT06733153T patent/ATE491695T1/de not_active IP Right Cessation
- 2006-03-31 WO PCT/NZ2006/000064 patent/WO2006104406A1/en not_active Ceased
- 2006-03-31 CA CA2603088A patent/CA2603088C/en not_active Expired - Fee Related
- 2006-03-31 AU AU2006229566A patent/AU2006229566B2/en not_active Ceased
- 2006-03-31 DE DE602006018883T patent/DE602006018883D1/de not_active Expired - Lifetime
- 2006-03-31 EP EP06733153A patent/EP1866292B1/de not_active Expired - Lifetime
- 2006-03-31 DK DK06733153.8T patent/DK1866292T3/da active
- 2006-03-31 US US11/887,368 patent/US7989451B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006229566A1 (en) | 2006-10-05 |
| EP1866292A4 (de) | 2010-01-20 |
| DE602006018883D1 (de) | 2011-01-27 |
| CA2603088A1 (en) | 2006-10-05 |
| US7989451B2 (en) | 2011-08-02 |
| CA2603088C (en) | 2015-05-26 |
| DK1866292T3 (da) | 2011-05-09 |
| US20090186886A1 (en) | 2009-07-23 |
| EP1866292A1 (de) | 2007-12-19 |
| AU2006229566B2 (en) | 2011-12-22 |
| EP1866292B1 (de) | 2010-12-15 |
| WO2006104406A1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001997A (es) | Compuestos biciclicos, composiciones y usos de los mismos. | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| TW200512205A (en) | Quinazoline derivatives | |
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| ES2391382T8 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
| ATE531263T1 (de) | Hemmer der bruton-tyrosinkinase | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| MX2009005011A (es) | Imidazopirazinas como inhibidores de proteina quinasa. | |
| ATE494899T1 (de) | Zusammensetzung bestehend aus phy906 und chemotherapeutika | |
| IL185391A0 (en) | Quinazolinone t-type calcium channel antagonists | |
| MX272108B (es) | Heterociclos sustituidos. | |
| TW200630105A (en) | Herbal composition PHY906 and its use in chemotherapy | |
| MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| DE60209721D1 (de) | Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore | |
| ATE522500T1 (de) | Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür | |
| MX2007004596A (es) | Nitrobenzoindoles y su uso en terapia del cancer. | |
| EA201070195A1 (ru) | ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРРОЛО [1,2-А]ПИРАЗИН-6-КАРБОКСАМИДОВ И 2,3,4,5-ТЕТРАГИДРОПИРРОЛО [1,2-a][1,4]-ДИАЗЕПИН-7-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| MX2010000223A (es) | Compuestos de triazina novedosos para el tratamiento de cancer. | |
| ATE491695T1 (de) | Tricylische 1,2,4-triazinoxide und zusammensetzungen davon zur therapeutischen anwendung bei krebsbehandlungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |